Αρχική World News Artificial Intelligence Brings Pancreatic Cancer Screening One Step Closer to Reality

Artificial Intelligence Brings Pancreatic Cancer Screening One Step Closer to Reality [ESMO World GI press release]

LUGANO, Switzerland – Artificial intelligence (AI) holds promise for enabling earlier detection of pancreatic cancer, which is crucial to saving lives. The potential of AI is showcased in a study to be presented at the ESMO World Congress on Gastrointestinal Cancer, 1-4 July 2020. (1)

Overall, 12 in every 100,000 people develop pancreatic cancer. This means that screening everyone would be inefficient and would expose many people to unnecessary tests and potential side-effects. Between 70–80% of patients are diagnosed at an advanced stage when it is too late for curative treatment and five years after diagnosis, just 6% of patients have survived.

Screening helps identify cancer early, when treatments are most effective, thus improving survival. There are two main requirements for screening. First, a screening test that is easy to perform and has few side-effects. Second, a defined group that would benefit most from screening because they are at higher risk. For example, breast cancer screening involves mammography in women aged 50 to 71 years. AI could be the desperately needed answer to define a group of higher risk individuals that would benefit from screening, especially as recently some promising results have indicated that non-invasive tests for pancreatic cancer may soon be available.

It is known that patients who develop pancreatic cancer consult their general practitioner (GP) with non-specific symptoms such as gastrointestinal problems or back pain more frequently in the months and years prior to diagnosis compared with their peers who do not develop pancreatic cancer. Individually, these symptoms are unlikely to trigger further investigations for cancer. Researchers came up with the idea that AI could find a combination of these non-specific symptoms that is linked with higher risk of contracting the disease, which would be difficult to spot by GPs.

This preliminary study used electronic health records from GP practices in the UK. (2) The analysis included 1,378 patients aged 15–99 years diagnosed with pancreatic cancer in 2005 to 2010. Each patient was matched by age and sex to four people who did not get pancreatic cancer. Information on symptoms, diseases, and medications in the two years prior to diagnosis were used to create a model predicting who would develop pancreatic cancer. 

malhotra-ananya

“We used AI to study a large volume of data and look for combinations that predict who will develop pancreatic cancer,” said study author Dr. Ananya Malhotra, research fellow in statistics, London School of Hygiene &Tropical Medicine, London, UK. “It’s not possible for the human eye to recognise these trends in such large amounts of data.”

The pilot study found that in people under 60 years of age, the model could predict who was at higher risk of pancreatic cancer up to 20 months before diagnosis. “Our model has estimated that around 1,500 tests need to be performed to save one life from pancreatic cancer,” explained Malhotra. “This is unlikely to be small enough to make screening viable just yet. However, it shows that AI holds potential to narrow down the number of people we need to screen. We should be able to reduce this quite a lot further by matching pancreatic cancer patients to controls from the general population, which is what we plan to do next (in the current study, the controls had other types of cancer).”

“Pairing this predictive model with a non-invasive screening test, followed by scans and biopsies, could lead to earlier diagnosis for a significant proportion of patients and a greater number of patients surviving this cancer,” added Malhotra.

Using AI to identify people at high-risk of pancreatic cancer up to 20 months earlier could make the difference between life and death. “This should be enough time to screen for pancreatic cancer, then proceed with diagnosis and treatment in patients with a positive screening test,” said Dr. Angela Lamarca, consultant in medical oncology, The Christie NHS Foundation Trust, Manchester, UK. “Early diagnosis in pancreatic cancer gives the highest chance of cure.”

According to Lamarca, GPs could use this type of AI model on their medical records to highlight patients at higher risk. An alarm could be raised showing who should receive screening. She said: “We need bigger studies incorporating AI tools into daily clinical practice and exploring the benefit of screening the patients selected by AI. More research is also needed to find a good screening test for these high-risk patients.”

References

  1. Abstract -SO-13 ‘Can we screen for pancreatic cancer? Identifying a sub-population of patients at high risk of subsequent diagnosis using machine learning techniques applied to primary care data’ will be presented by A. Malhotra during Session V: Molecular Screening; Imaging; Artificial Intelligence on Thursday, 2 July 2020, 18:50 to 20:21 (CEST). Annals of Oncology: doi.org/10.1016/j.annonc.2020.04.028
  2. This study was funded by the Pancreatic Cancer Research Fund

SO-13 – Can we screen for pancreatic cancer? Identifying a sub-population of patients at high risk of subsequent diagnosis using machine learning techniques applied to primary care data

A. Malhotra1, B. Rachet1, A. Bonaventure2, S. Pereira3, L. Woods1

1London School of Hygiene and Tropical Medicine, London, United Kingdom; 2CRESS, University of Paris, Paris, France; 3UCL Institute for Liver and Digestive Health, London, United Kingdom

Background: Ninety-four percent of pancreatic cancer patients die within 5 years of their diagnosis. Most patients experience no obvious symptoms until the tumour is well advanced. It is now possible, via a blood test, to detect pancreatic cancer before symptoms of late-stage disease are evident. However, in order to be cost-effective, this test should only be applied to a limited group of individuals.

Methods: We conducted a national, population-based, case-control study to deter-mine whether it is possible to identify a sub-population of patients at high risk of developing pancreatic cancer. Our hypothesis was that patients with early malignancy share similar profiles of early, diffuse, warning signs which might be detectable through the application of machine learning approaches. We used the Clinical Practice Research Datalink (CPRD), linked to the national cancer registrations. Our cases comprised of 1,378 patients, aged 15-99 years, diagnosed with pancreatic cancer between 1 January 2005 and 31 December 2010. Each case was individually age- and diagnosis time-matched to four non-pancreatic (cancer) controls. Disease, symptom and prescription codes for the 24 months prior to diagnosis were used to define 58 individual symptoms. Using a machine learning approach, we fitted logistic regression and random forest models. These models were trained on 75% of the data and tested on the remaining 25%.

Results: Preliminary results show that diagnosis could be accurately predicted for 60%of the patients below the age of 60 using their medical history recorded between 20-24 months before diagnosis with an AUC of 61%, sensitivity of 76% and a specificity of 45%.

Conclusion: A sub-population of patients later diagnosed with pancreatic cancer is detectable up to 20 months before diagnosis. Further work should test the performance of the model for longer time periods as well as its effectiveness in a population-based setting. These data suggest that early detection of pancreatic cancer is possible. Pairing this predictive model with a screening test could lead to earlier diagnosis and a greater number of patients surviving this devastating disease.

Legal entity responsible for the study: The authors.

Funding: Pancreatic Cancer Research Fund.

Disclosure: The presenting author has declared no conflicts of interest.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...

Prostate Cancer

The article is provided by Scientific Communications Officer of NIPD Genetics, Ms Marina Charitou (MSc) Prostate Cancer Awareness Prostate cancer is the second most common cancer...
- Advertisment -

Ροή Ειδήσεων

ESMO 2020: New Treatments for Advanced Kidney Cancer, Prostate Cancer, and Bladder Cancer

The 2020 European Society for Medical Oncology (ESMO) Virtual Congress was held online from September 19 to September 21. In this podcast, Neeraj Agarwal,...

The UK Government’s spending review: Time to invest in the future of cancer care

This autumn, the chancellor Rishi Sunak will go to Parliament and set out the UK Government’s spending priorities in the Comprehensive Spending Review...

FDA Extends Approval of Pembrolizumab for Classical Hodgkin Lymphoma

On 14 October 2020, the US Food and Drug Administration (FDA) extended the approval of pembrolizumab (KEYTRUDA®, Merck Sharp & Dohme Corp.) for the...

31-Year-Old Mother Dies of Cancer After Her Chemotherapy Was Paused During the Pandemic

The COVID-19 pandemic has been a scary and difficult thing for most of the world, and it’s important to keep safety protocols in place...

For Esophageal Cancer, Immunotherapy Likely to Play Larger Role

October 19, 2020, by NCI Staff An esophagram using barium contrast shows the esophagus. Credit: iStock Immunotherapy may become part of early treatment for some people with...

Targeted Therapy Based on Molecular Profiling of Malignant Mesothelioma Tumours Is Feasible

Targeted therapy recommendations can be made based on the molecular profiles of tumour samples from patients with metastatic malignant mesothelioma (MM) according to findings...